BioNTech hopes to move into cancer drugs
Losses at German pharmaceutical company BioNTech quadrupled in the second quarter compared to the previous year. Now the company is confident in a change of strategy towards new cancer treatments after a sharp drop in sales of its COVID-19 vaccine. BioNTech reported a second-quarter net loss of €807.8 million.
ENTRADAS POPULARES
Poland prepares for peaking floods
septiembre 20, 2024
Italy evacuates thousands as Boris hits the north
septiembre 20, 2024
China and the US race to tame nuclear fusion for clean energy
septiembre 20, 2024
TRANSMISIÓN EN VIVO